Phase Forward Ranked 16th in Globe 100

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, has been named to the "Globe 100” list of top-performing public companies in Massachusetts. Based on a composite score derived from financial data for the four quarters ending December 31, 2007, Phase Forward was ranked 16th among Massachusetts-based companies whose stock is publicly traded on NASDAQ, New York Stock Exchange or American Stock Exchange. It is the second time Phase Forward has been included in the Globe 100. Phase Forward consistently merits inclusion in the Boston Globe’s weekly listing of the "Life Sciences 25,” a roster of the top companies in the sector, ranked by market value. The company also boasts recent product wins including the prestigious Bio-IT World Best Practices award for Lincoln Safety Group’s Clinical Trials Signal Detection (CTSD™) product. "These companies represent the resiliency of Massachusetts business, surviving recessions, merger manias and dramatics shifts in their industries,” said Shirley Leung, business editor of the Boston Globe. "As a software and service company providing products to the life sciences industry, Phase Forward is at a unique intersection – one that allows us to draw on two thriving local Massachusetts markets,” said Bob Weiler, CEO and president, Phase Forward. "The state’s strong roots in technology provide a natural foundation for companies like Phase Forward, as well as an inherent spirit of innovation and collaboration of which we’re proud to be a part. We’ll continue to work with other leading companies and world-renowned academic institutions to drive growth in the state.” Phase Forward closed 2007 with record revenues of $134 million, up 26 percent from 2006, and announced a 26 percent increase in revenues for the first quarter of 2008 over the same quarter last year. Later this year the company will move its headquarters to one of the suburb’s greenest buildings, 77 CityPoint in Waltham, to further expand and accommodate growth. The Globe 100, now in its 20th year, ranks Massachusetts-based public companies based on financial data from the four quarters ending closest to December 31, 2007, and for corresponding quarters a year earlier. About The Boston Globe The Boston Globe is wholly owned by The New York Times Company (NYSE: NYT), which is a leading media company with 2007 revenues of $3.2 billion, and includes The New York Times, the International Herald Tribune, The Boston Globe, 16 other daily newspapers, WQXR-FM and more than 50 Web sites, including NYTimes.com, Boston.com and About.com. The Company’s core purpose is to enhance society by creating, collecting and distributing high-quality news, information and entertainment. About Phase Forward Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm(TM)), phase I clinic automation (LabPas(TM)), clinical data management (Clintrial(TM)), clinical trials signal detection (CTSD(TM)), strategic pharmacovigilance (WebVDME(TM) and Signal Management), adverse event reporting (Empirica(TM) Trace) and applied data standards (WebSDM(TM)). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 280 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com. Cautionary Statement Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, Phase Forward's expectations and assumptions concerning management’s forecast of financial performance, the performance of Phase Forward’s products and services, future business and operations plans of Phase Forward’s customers, the ability of Phase Forward’s customers to realize benefits from the use of Phase Forward’s products and services, and management’s plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, changes in our customers’ industries; our ability to convince prospective customers to adopt our solutions; competition; changing customer requirements; governmental regulation; our ability to maintain profitability; fluctuations in our operating results; long sales and implementation cycles; our dependence on a limited number of customers or suppliers; product performance; third party service interruptions or delays; technology failures; our ability to maintain customer relationships and contracts; our ability to retain and hire skilled personnel; our ability to protect our intellectual property rights; product liability or intellectual property infringement claims brought against us; acquisitions; our ability to manage our rapid growth; our ability to obtain capital when desired on favorable terms; and the volatility of the market price of our common stock. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.